Sabby Management’s Checkpoint Therapeutics CKPT Stock Holding History

Sabby Management’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-354	Closed	-$24.6K	–	47
2025 Q1	$24.6K	Sell	354 -1,450	-80%	-$4.83K	0.07%	42
2024 Q4	$577K	Buy	1,804 +43	+2%	+$146	0.75%	15
2024 Q3	$394K	Sell	1,761 -947	-35%	-$2.19K	0.21%	14
2024 Q2	$582K	Buy	2,708 +335	+14%	+$596	0.39%	9
2024 Q1	$486K	Buy	2,373 +1,421	+149%	+$2.83K	0.28%	12
2023 Q4	$218K	Buy	+952	New	+$2.07K	0.22%	21

Sabby Management's CKPT Position: Q4 2023 in Review

Sabby Management sold out of Checkpoint Therapeutics (CKPT) in Q4 2023, closing a stake of 205,247 shares — an estimated $447K sold.

Sabby Management first reported a position in CKPT in Q3 2020 and held it in 2 quarters. The position peaked at $2.5M in Q3 2020. 43 funds tracked by Wall St. Rank hold CKPT as of Q4 2023.

Sabby Management reported no remaining Checkpoint Therapeutics position as of Q4 2023 after selling out during the quarter.
Sabby Management sold 205,247 Checkpoint Therapeutics shares in Q4 2023, an estimated $447K.
Sabby Management first reported a position in Checkpoint Therapeutics in Q3 2020 and held it in 2 quarters.
Sabby Management's Checkpoint Therapeutics position peaked at $2.5M in Q3 2020.
43 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2023.

Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.